AOL Money & Finance

Option Update; Myriad Genetics volatility Elevated into disappointing Alzheimer's data

More

Myriad Genetics (NASDAQ:MYGN) is recently down $5.48 to $42.25 in pre-open trading. MYGN's Flurizan, a treatment for Alzheimer's diseases, had negative Phase 3 results. RBC Capital has a 12-month forward target of $37 on MYGN. MYGN July option implied volatility of 102 was above its 26-week average of 71 according to Track Data, suggesting larger July price movement.


Option Update is provided by Stock Specialist Paul Foster of theflyonthewall.com

Symbol Lookup
IndexesChangePrice
DJIA+132.7910,450.95
NASDAQ+29.972,176.01
S&P 500+14.861,106.24

Last updated: November 24, 2009: 07:07 AM

BloggingStocks Exclusives

Hot Stocks

DailyFinance Headlines

Latest from BloggingBuyouts

TheFlyOnTheWall.com Headlines

BioHealth Investor Headlines

WalletPop Headlines

My Portfolios

Track your stocks here!

Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

BloggingStocks Partners

More from AOL Money & Finance

WalletPop Headlines